Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population‐Based Cohort Study
Autism Research · 2026
DOI: 10.1002/aur.70302 ↗At a glance
Kohortenstudie in Autism Research, 2026. Written by Vincent Chin-Hung Chen and 5 co-authors. Institution: Departments of Psychiatry and Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan. Major MEDLINE topics: Autism Spectrum Disorder, Antidepressive Agents. 51 references.
Abstract (original language)
Individuals with autism spectrum disorder (ASD) often experience premature mortality and co‐occurring psychiatric conditions, for which antidepressants are commonly prescribed. However, the long‐term safety of antidepressant use in this population remains unclear. Using data from the Taiwan National Health Insurance Research Database, we emulated a target trial to examine the association between antidepressant use and mortality among individuals with ASD aged 6–64 years diagnosed between 2000 and 2016. A three‐step approach of cloning, censoring, and inverse probability of censoring weighting was applied to address immortal‐time bias. Participants were followed for up to 5 years to assess all‐cause, suicide, and accidental‐cause mortality. Among 33,939 eligible individuals, 779 initiated antidepressants within a 3‐month grace period. Antidepressant use was not associated with all‐cause or suicide mortality overall. However, it was significantly associated with reduced accidental‐cause mortality at both 2 (HR = 0.15; 95% CI, 0.04–0.53) and 5 years (HR = 0.05; 95% CI, 0.01–0.20). Subgroup analysis revealed increased 2‐year all‐cause mortality among youths (HR = 4.40; 95% CI, 1.10–17.58) but significantly decreased 5‐year accidental mortality in the age groups of 6–15 years (HR = 0.06; 95% CI, 0.01–0.41) and over 24 years (HR = 0.06; 95% CI, 0.01–0.42). Additionally, decreased 5‐year suicide mortality was observed in the 16–24 age group (HR = 0.17; 95% CI, 0.05–0.61). While antidepressant use may reduce accidental mortality in individuals with ASD, age‐specific risks warrant careful consideration and monitoring, particularly among younger populations.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Departments of Psychiatry and Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan.
- School of Medicine, Chang Gung University, Taoyuan, Taiwan.
- School of Medicine, MacKay Medical University, New Taipei City, Taiwan.
- Section of Psychiatry, MacKay Memorial Hospital, Taipei City, Taiwan.
- Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.
- Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Cite
APA
Chen, V. C., Huang, Y. H., Chen, Y. L., Dewey, M. E., Hung, T. H., & Wu, S. I. (2026). Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population‐Based Cohort Study. Autism Research. https://doi.org/10.1002/aur.70302
Vancouver
Chen VC, Huang YH, Chen YL, Dewey ME, Hung TH, Wu SI. Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population‐Based Cohort Study. Autism Research. 2026. doi:10.1002/aur.70302
BibTeX
@article{Chen2026,
author = {Chen, Vincent Chin-Hung and Huang, Yu-Hsin and Chen, Yi-Lung and Dewey, Michael E and Hung, Tai-Hsin and Wu, Shu-I},
title = {Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population‐Based Cohort Study},
journal = {Autism Research},
year = {2026},
doi = {10.1002/aur.70302}
}
EUVIMED